TrialJournal of Crohn's & colitis2026

Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.

Severine Vermeire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.